Michael A. Weber, MD, PhD
Dr. Michael Weber is a Professor of Medicine at Downstate College of Medicine of the State University of New York. He received his medical degree from Sydney University in Australia.
His career has focused largely on hypertension and preventive cardiology. He has been a leading part of several of the clinical trials that have helped define strategies for optimizing cardiovascular protection for patients with hypertension. He has also been very much involved with new drug development going back to the beta blockers and through to the contemporary angiotensin receptor blockers.
Dr. Weber is an author of over 500 articles in the peer-reviewed literature and has authored or edited 16 books. He was a founder of the American Society of Hypertension (ASH) and the ASH Hypertension Clinical Specialists Accreditation Program and has served as President of both those organizations. Dr. Weber maintains a strong interest in global hypertension issues and is a member of the Executive Committee of the International Society of Hypertension. He was Chair of the Writing Committee of the 2014 ASH/ISH Hypertension Clinical Practice Guidelines
He is currently Editor-in-Chief of the Journal of Clinical Hypertension, the official Journal of the World Hypertension League. He is a Fellow of The American College of Physicians, The American College of Cardiology and The American Heart Association. He has served on the Cardiovascular and Renal Drugs Advisory Board of the Food and Drug Administration and continues as a consultant to that Agency. He has also served as Chairman of the Formulary Committee of a major pharmacy benefits provider serving many of the leading health plans in the United States.
His main research interests are in clinical trials of patients at high risk of cardiovascular events or strokes. He is also participating actively in trials in patients with metabolic disorders such as diabetes and kidney disease. Dr. Weber currently serves on the Steering Committees of several national and international clinical outcomes trials.